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engagement. ConClusions: The evidence-based market access value resource 
approach provides a clear, concise, and globally integrated value story that will 
assist in market access and form the basis of consistent communication regarding 
value at the national, regional, and local level across external stakeholders (e.g., 
payer decision makers, physicians, patient advocates). Access for a biologics will be 
complex; regardless of pathway, decisions regarding reimbursement and adoption 
of a new technology are diverse and dispersed across and within countries, with 
varying levels of required evidence.
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The US significantly outspends all other top 10 developed nations, with no increase 
in life expectancy. Increasing transparency in health care spending could help 
address this cost to outcomes gap. CMS’ recent release of Medicare Part B Utilization 
and Payment data, covering 880,000 providers and $77 billion in Medicare pay-
ments, is a significant step toward this goal. objeCtives: Understand differences 
in billed versus paid amounts for provider and procedure types reported in Medicare 
data. Methods: Descriptive and inferential statistics were run on provider spe-
cialties representing greater than 2% of claims to describe the differences between 
maximum allowed Medicare payment amount, amount billed by providers, and 
the amount reimbursed. Geographical variation was also explored. Results: 
Amount billed is at least double the amount paid and double the maximum allow-
able amount for all of the specialties explored; amount billed versus paid varies 
significantly by specialty, with some specialties billing as much as six times what 
they are paid. Largest discrepancies were in anesthesiology (on average billing $838, 
versus $139 allowed and $110 paid). Other specialties with significant disparity 
include cardiology, diagnostic radiology, emergency medicine, ophthalmology, and 
orthopedic surgery; within certain specialties, specific procedures showed ranges 
of billing and payment ratios; across all specialties, average amount paid was about 
90% of maximum allowable; and each state is represented in line with census data 
for the Medicare population; state differences in amount paid versus billed and 
allowed is not significant. ConClusions: In analyzing payer and provider data to 
increase transparency on health care spend, we recognize there is heterogeneity 
between what is paid versus billed across specialty. There is an opportunity to focus 
attention on narrowing this gap for high-value procedures through evidence and 
education of patients, payers, and providers to ensure patients receive appropriate 
treatment, and providers are appropriately reimbursed.
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objeCtives: To assess the value and service quality of the National Health 
Insurance Scheme (NHIS) benefits. Methods: A review method was employed 
to analysis medical claims for the 2011 to 2013 period. The medical claims were 
retrieved from the database of the Ashiedu Keteke District NHIS Office. The incurred 
claims ratio, promptness of claims settlement, and claims rejection ratio indicators 
of benefit value and service quality were analyzed. Results: A total of 421,574 
medical claims with a cost of GHS7.3 million (USD2.6 million) were analyzed. 
These claims came from thirteen accredited health care providers-three public 
health facilities, four private clinics and six community pharmacies. The incurred 
claims ratio increased significantly from 4.3 to 7.2 over the period, 2011-2013. The 
proportion of claims settled beyond 90 days increased consistently from 26% to 
90% over the same period. Although, the proportion of claims rejected increased 
from 0.9% to 3.6% over the period under review, overall, it was low. The reasons for 
rejection included provision of benefits to inactive subscribers and breach of sub-
limit on certain expense category. ConClusions: There is increased awareness 
and utilization of health services; however, there are considerable delays in claims 
settlements. It would be necessary for management of the NHIS to settle claims 
in time to ensure that health care providers are financially resourced to render 
service to subscribers.
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objeCtives: Our team wanted to compare the economic effect of restricted mar-
ket access and reference based pricing (RBP) vs. RBP alone in two consecutive 
periods, 2007—2009 and 2010—2012. Methods: We used the officially published 
cash flow statements and income statements from the financial reports of the 
National Health Insurance Fund (NHIF) for each of the years from 2007 to 2012. 
Then we compared the data about the expenditure for drugs, as well as the data 
about the budget control. Results: While restricted market access and RBP has 
been applied between 2007 and 2009, the NHIF drug expenditure increased with 
15% (from EUR 144 mln to EUR 166 mln). For that period, the drug expenditure 
was generally 100% within the budget. From 2010 to 2012, while only RBP has been 
applied, the expenditure increased with 62% (from EUR 187 to EUR 303 mln). For 
the period, the drug expenditure exceeded the NHIF budget with 5% in 2010, 34% in 
2011, 20% in 2012. ConClusions: RBP alone cannot control the drug expenditure 
in a long-term. Additional measures are needed together with RBP. Performance-
based pricing, differential pricing, comparative pricing, profit control and price-
volume agreements may be considered as additional to RBP measures for pricing 
and budget control.
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objeCtives: The part of Hungarian drug provision system, which is available 
on social welfare list, changed several times and in different extents in recent 
years. The introduction of drug budget in 2006 and simultaneously the abolition 
of social welfare drug list implied the most significant change. The chief aim of 
our analysis to give a comprehensive overview about the main trends on this field 
examining the range of available products on social welfare list based on different 
aspects, also concerning the trends of demand, product structure, expenditures 
and patient burdens. Methods: Changes of key points of relevant acts concerned 
in drug provision, the aggregated (not patient level) public turnover data of the 
Hungarian Health Fund and published number of patients involved in this reim-
bursement category were considered as the key sources and indicators of our 
evaluation. Results: After regulation changes, demand (DOT) and number of 
patients within social welfare list category significantly decreased after 2006 until 
2009, but since then both of them stagnate. Significant growth of reimbursement 
outflow within this segment can be observed until 2011, but after slight decrease. 
Part share of higher level reimbursement categories within reimbursement out-
flow increased. Demand moved to more expensive products, while patients were 
able to access to more innovative active ingredients in higher level reimburse-
ment categories. Strong correlation can be observed between changes of acts and 
breaks in turnover trends. ConClusions: Results of the analysis may support 
objective judgement of the present social welfare provision system, as well as 
may contain considerable consequences regarding to potential ways of future 
structural changes, considering both interests of entitled patients (right to access 
innovative therapies) and the Health Fund (increase savings, improve efficiency). 
Further analysis based on real world (patient level) data may result more complex 
investigation opportunities of this patient segment and reimbursement category.
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objeCtives: This study aims to determine if the recently proposed model for thera-
peutic positioning reports (IPTs) in Spain is actually being used as a supportive 
tool for pharmaceutical pricing and reimbursement (P&R) decisions whilst deliver-
ing greater transparency and regional market access harmonisation. Methods: 
Primary research was conducted with regional payers on the proposed model of 
IPTs, which contain a comparative evaluation on effectiveness and safety, as well 
as criteria of use, for newly authorized medicines and older medicines which have 
a high potential health or economic impact. This was supplemented by secondary 
research. Results: The publication of IPTs has brought quicker uptake and greater 
homogenization to the market access of certain medicines. Notably, according to 
primary research, protease inhibitors were made available in all autonomous com-
munities (CCAAs) two months after the IPT publication. However, the deadline of 3 
months for the publication of IPTs is generally not being met. As delineated in the 
model and shown by primary research, IPTs are starting to be used as a basis for 
P&R decision-making in Spain and play an important role in the identification of 
the most suitable target patient population. IPTs are also delivering on promises 
of generating consensus amongst the Spanish CCAAs. ConClusions: IPTs are 
being used to support the Inter-ministerial Commission of Medicine Prices and 
the Directorate General of Pharmacy and Basic Services role in P&R. If accepted 
by the majority of the CCAAs, IPTs will also serve as a tool to evaluate and limit 
discrepancies in innovative medicines access throughout Spain. However, there is 
lack of consensus of whether an IPT should include an economic evaluation from 
the start. Contrary to manufacturers, regional payers generally believe its inclusion 
would help with the selection of more cost-effective medicines whilst aiding with 
the adoption of IPTs in general.
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objeCtives: Referral utilization is defined as the number of patients referred and 
seen by physicians. The objective was to establish referral utilization rate among sick 
persons identified at the households, counseled and referred to link hospitals by com-
munity health workers. Sick persons identified were issued with referral and counter 
referral slips to take to the hospital. Methods:  This was a quasi -experimental study 
carried out in two sub- locations in rural Kenya. One hundred community health 
workers were trained on community based referral and counter referral model and 
issued with referral tools. Each was assigned 25 households, instructed to regularly 
visit them in order to identify sick persons, counsel and refer them to link hospitals for 
care. One hundred villages comprising 2209 households with a population of 11,000 
people were covered and referral model implemented for 12 months. Results: A 
total of 322 patients were identified, advised and referred, with a referral response 
rate of 93% (298/322.) Seventy percent were five years and above. The study showed 
that 82% (263/322) of the patients arrived in hospital with referral slip the same day 
